

## Revlimid - (5, 10, 15, 25 mg; Capsule, Oral)

|                              |  |                             |                     |
|------------------------------|--|-----------------------------|---------------------|
| <b>Generic Name</b>          | Lenalidomide   | <b>Innovator</b>            | Celgene             |
| <b>Dosage</b>                | 5, 10, 15, 25 mg; Capsule, Oral  | <b>Branded US Sales</b>     | More Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5  | <b>Known Para IV Filers</b> | More Than 5         |
| <b>Other ANDA developers</b> | More Than 5  | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | More Than 5  | <b>Generic Launches</b>     | More Than 5         |
| <b>Indication</b>            | Indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. |                             |                     |
| <b>Complexities</b>          | Yes  |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Revlimid - (2.5, 20 mg; Capsule)

|                              |   |                             |                     |
|------------------------------|---|-----------------------------|---------------------|
| <b>Generic Name</b>          | Lenalidomide  | <b>Innovator</b>            | Celgene             |
| <b>Dosage</b>                | 2.5, 20 mg; Capsule   | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5   | <b>Known Para IV Filers</b> | More Than 5         |
| <b>Other ANDA developers</b> | More Than 5   | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | More Than 5   | <b>Generic Launches</b>     | More Than 5         |
| <b>Indication</b>            | REVLIMID is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities |                             |                     |
| <b>Complexities</b>          | Yes   |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.